ClinicalTrials.gg
Active, not recruitingNCT06507306Updated Sep 2, 2026

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

A Phase 1 interventional study of KQB198 and Osimertinib in Solid Tumor, Adult, sponsored by Kumquat Biosciences Inc.. Active, not recruiting at 26 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Kumquat Biosciences Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
92
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are:

  • What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs?
  • Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor?
  • What happens to KQB198 in the body?

Participants will:

  • Take KQB198 daily, alone or in combination with another anti-cancer drug
  • Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that
02

Conditions studied

  • Solid Tumor, Adult
03

In context

Lead sponsor

Kumquat Biosciences Inc. is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PART 1 - confirmed diagnosis of a solid tumor with any of the following oncogenic mutations: EGFR, RAS, PTPN11, or SOS1 mutations, or inactivating mutations of NF1.
  • PART 1 - (Osimertinib and Amivantamab arms) and Part 2 Cohort A and Cohort B: Histologically confirmed diagnosis of NSCLC with activating EGFR mutation and progression on osimertinib
  • Part 3 - Cohort A: Histologically confirmed diagnosis of NSCLC with exon 20 insertion EGFR mutation
  • Unresectable or disease
  • No available treatment with curative intent
  • Adequate organ function
  • per 1.1.

Exclusion criteria

Exclusion Criteria:

  • Prior therapy with a similar mechanism of action to KQB198
  • History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow
  • History of interstitial lung disease
  • Cardiac abnormalities
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Monotherapy Dose Escalation

    Drug: KQB198

  • Experimental
    Combo Therapy Dose Escalation

    Drug: KQB198 · Drug: Osimertinib · Drug: Amivantamab

  • Experimental
    Combo Therapy Dose Expansion - RP2D

    Drug: KQB198 · Drug: Osimertinib · Drug: Amivantamab

  • Experimental
    Combo Therapy Dose Expansion - RP2D-1

    Drug: KQB198 · Drug: Osimertinib · Drug: Amivantamab

  • Experimental
    Combo Therapy Dose Expansion OBD

    Drug: KQB198 · Drug: Osimertinib · Drug: Amivantamab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of patients who experience treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities (Part 1)

    Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of AEs, SAEs, and DLTs, from first dose of study treatment to 28 days after last dose of study treatment.

    Time frame: 28 Days

  2. Recommended Phase 2 Dose (RP2D) (Part 1)

    Evaluate safety and assess number of patients with dose-limiting toxicity to determine the RP2D.

    Time frame: up to 30 months

  3. Efficacy and Optimal Biologic Dose of study treatment, as measured by Objective Response Rate (ORR) (Parts 2 and 3)

    Objective response is the proportion of subjects that experience confirmed complete response (CR) or partial response (PR) based on RECIST v1.1 during the time period from 1st dose of study treatment until last dose.

    Time frame: up to 30 months

Secondary outcomes

  1. Concentration-time curve (AUC)

    Time frame: up to 30 months

  2. Maximum plasma concentration (Cmax)

    Time frame: up to 30 months

  3. Time to maximum plasma concentration (tmax)

    Time frame: up to 30 months

  4. Overall survival (OS)

    Time frame: up to 30 months

  5. Progression-free survival (PFS)

    Time frame: up to 30 months

  6. Overall response rate (ORR)

    Time frame: up to 30 months

  7. Duration of response (DOR)

    Time frame: up to 30 months

  8. Time to response (TTR)

    Time frame: up to 30 months

07

Study locations

26 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2024
First posted
Jul 18, 2024
StartActual
Jun 3, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jan 31, 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06507306
Lead sponsor
Kumquat Biosciences Inc.
Responsible party
Sponsor
First posted
Jul 18, 2024
Start date
Jun 3, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Sep 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SOS1 Inhibitor MRTX0902

Start the discussion